SOCIAL AND HEALTH SERVICES
(Medical Assistance Administration)
Title of Rule and Other Identifying Information: WAC 388-530-1280 Preferred drug list(s).
THIS RULE IS BEING PROPOSED UNDER AN EXPEDITED RULE-MAKING PROCESS THAT WILL ELIMINATE THE NEED FOR THE AGENCY TO HOLD PUBLIC HEARINGS, PREPARE A SMALL BUSINESS ECONOMIC IMPACT STATEMENT, OR PROVIDE RESPONSES TO THE CRITERIA FOR A SIGNIFICANT LEGISLATIVE RULE. IF YOU OBJECT TO THIS USE OF THE EXPEDITED RULE-MAKING PROCESS, YOU MUST EXPRESS YOUR OBJECTIONS IN WRITING AND THEY MUST BE SENT TO Rules Coordinator, Department of Social and Health Services, P.O. Box 45850, Olympia, WA 98504-5850 , AND RECEIVED BY 5:00 p.m., on May 2, 2005.
Purpose of the Proposal and Its Anticipated Effects, Including Any Changes in Existing Rules: To correct a typographical error in a cross-reference. The introduction to WAC 388-530-1280 refers to RCW 69.41.090; the correct reference is RCW 69.41.190.
Reasons Supporting Proposal: To ensure the correct cross-reference is cited. RCW 34.05.353 (1)(c) allows using the expedited rule-making process to correct typographical errors.
Statutory Authority for Adoption: RCW 74.08.090, 70.14.050, 69.41.190.
Statute Being Implemented: RCW 69.41.190.
Rule is not necessitated by federal law, federal or state court decision.
Name of Proponent: Department of Social and Health Services, governmental.
Name of Agency Personnel Responsible for Drafting: Ann Myers, P.O. Box 45503, 925 Plum Street S.E., Olympia, WA 98504, (360) 725-1345; Implementation and Enforcement: Siri Childs, P.O. Box 45506, 805 Plum Street S.E., Olympia, WA 98504, (360) 725-1564.
February 25, 2005
Andy Fernando, Manager
Rules and Policies Assistance Unit3519.1
(1) The Washington preferred drug list (PDL):
(a) Washington state contracts with evidence-based practice center(s) for systematic reviews of drug(s).
(b) The pharmacy and therapeutics (P&T) committee reviews and evaluates the safety, efficacy, and outcomes of prescribed drugs, using evidence-based information provided by the evidence-based practice center(s).
(c) The P&T committee makes recommendations to state agencies as to which drug(s) to include on the Washington PDL, under chapter 182-50 WAC.
(d) The appointing authority makes the final selection of drugs included on the Washington PDL.
(e) Nonpreferred drugs within a therapeutic class on the Washington PDL are subject to the therapeutic interchange program (TIP) according to WAC 388-530-1290.
(2) The medical assistance administration's (MAA's) PDL. Drugs on MAA's PDL:
(a) Are not part of the Washington PDL;
(b) Are not subject to TIP; and
(c) Continue to require prior authorization when they are designated as nonpreferred.
(3) Combination drugs that are not on the Washington PDL, that are not reviewed by the evidence-based practice center(s), and that are not subject to TIP under WAC 388-530-1290, are considered for coverage according to MAA's prior authorization program.
[Statutory Authority: RCW 74.08.090, 70.14.050, 69.41.150, 69.41.190, chapter 41.05 RCW. 05-02-044, § 388-530-1280, filed 12/30/04, effective 1/30/05.]